Compare Crispr Therapeutics AG (CRSP) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Alliant Energy Corporation — how do they compare? Crispr Therapeutics AG trades at $53.84 (market cap $5.23B), while Alliant Energy Corporation trades at $69.6 (market cap $17.78B). The key difference: Alliant Energy Corporation is far larger — about 3.4× Crispr Therapeutics AG's market cap, and Alliant Energy Corporation pays a 3.12% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | LNT | |
|---|---|---|
Market Cap | $5.23B | $17.78B |
Sector | Health | Utilities |
52-Week High | $76.78 | $78.03 |
52-Week Low | $44.34 | $63.62 |
Enterprise Value | $3.65B | $29.88B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Alliant Energy (LNT) trades at $68.21, down 1.67% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.65, beating estimates, and reaffirmed full-year guidance. Revenue grew to $4.36B in 2025, with net income margin at 18.45%. Analyst consensus is a Buy with a $77.67 price target, indicating potential upside. Recent news highlights institutional activity, including Assenagon Asset Management increasing its stake by 339.9% as of August 12, 2026.
LNT presents a stable investment opportunity with consistent earnings beats and a dividend yield, but faces risks from rising debt levels and bearish technical trends. The stock's valuation metrics, including a P/E of 21.7, are reasonable for the utilities sector. Upside is supported by analyst targets, while headwinds include higher interest costs and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
